Frederick Durand

TL;DR: The timely and effective use of patient-reported outcomes (PROs) could encourage physicians to focus more on the impact of RA on patients and how patients are feeling, ultimately leading to a more patient-centered approach and improved patient care.

TL;DR: In RA patients with an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than adalimumab and placebo, and analyses suggest the relationship between inflammation and pain may be different for baricit inib and ad alimumab treatments.

TL;DR: This post-hoc analysis investigated the effect of select comorbidities on the efficacy and safety of baricitinib 4 mg once daily in patients with moderate-to-severe active RA and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

TL;DR: A significant pain improvement of ≥70% was achieved at week 12 for pts treated with bari 4 mg compared to PBO (both studies) and ADA (RA-BEACON).